Cardio-Renal Division Acting Director To Be Throckmorton; Lipicky Retires
Executive Summary
Deputy Director Douglas Throckmorton, MD, will be acting director of FDA's Division of Cardio-Renal Drug Products starting Feb. 28, when long-time Division Director Raymond Lipicky, MD, retires
You may also be interested in...
Can Drugs Really Treat Sarcopenia? Some Patients Are Doubtful
Companies developing treatments for sarcopenia ‘have no idea what they're doing’, according to Ray Lipicky, a former director of the FDA’s Cardio-Renal Drug Products Division who spoke as a patient at the US agency’s sarcopenia drug development meeting.
FDA Standards Should Emphasize Larger Trials, Lipicky Tells ACC
FDA should move toward the Cardio-Renal Drug Products Division's requirement for extremely large trials as an approval standard, former Division Director Raymond Lipicky, MD, said
FDA Standards Should Emphasize Larger Trials, Lipicky Tells ACC
FDA should move toward the Cardio-Renal Drug Products Division's requirement for extremely large trials as an approval standard, former Division Director Raymond Lipicky, MD, said